市场调查报告书
商品编码
1464795
分子诊断自动化市场:按类型、应用和最终用途划分 - 2024-2030 年全球预测Automation in the Molecular Diagnostics Market by Type (Amplification Automation, Analysis Automation, Extraction Automation), Application (Blood Screening, Genetic Testing, Infectious Diseases), End-use - Global Forecast 2024-2030 |
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
预计2023年分子诊断自动化市场规模为117.5亿美元,预计2024年将达到135.4亿美元,2030年将达到328.1亿美元,复合年增长率为15.79%。
分子诊断中的自动化是指使用先进的技术和机械来执行复杂的实验室测试,检测和测量患者样本(例如血液、唾液和组织)中是否存在遗传物质(例如 DNA 和 RNA)。与需要大量体力和时间的传统方法不同,自动化简化了这些流程,使其更快、更准确,并且能够同时处理大量测试。人们对个人化医疗保健和精准医疗的日益关注需要更有效率、更准确的诊断。此外,全球慢性病盛行率的不断上升正在推动对自动化分子诊断设备的需求。医疗保健基础设施和研究方面的各种政府计划和资金正在支持这些技术的采用。然而,自动化技术的初步投资对于小型实验室和机构来说是令人望而却步的。此外,自动化技术的持续创新,例如高通量系统和人工智慧集成,将推动市场向前发展。整合人工智慧和机器学习以增强诊断中的资料分析和解释为製造商提供了重大机会。
主要市场统计 | |
---|---|
基准年[2023] | 117.5亿美元 |
预测年份 [2024] | 135.4亿美元 |
预测年份 [2030] | 328.1亿美元 |
复合年增长率(%) | 15.79% |
高通量环境中扩增自动化的重要性日益增加
自动扩增涉及将遗传物质(DNA 或 RNA)扩增至可检测水平并创建多个副本的过程。这是识别病原体和基因突变的分子诊断以及任何需要大量遗传物质进行分析的应用中的关键步骤。在需要一致、快速处理大量样本的高通量环境中,例如在感染疾病爆发或大规模基因检测中,自动化扩增尤其重要。自动分析涉及对扩增遗传物质的自动解释。这包括基于软体的变异检测、定量和突变识别分析。对于希望最大限度地减少资料解释中的人为错误的实验室以及需要快速週转时间而不影响准确性的实验室来说,自动化分析至关重要。萃取自动化是指从样本中自动提取核酸 (DNA/RNA) 的过程,是大多数分子诊断通讯协定的第一步。这种类型的自动化确保了核酸的高纯度和产量,对于后续诊断步骤的成功至关重要。分析后自动化包括自动化分析后资料管理,包括报告、资料储存和结果通讯。这确保了诊断结果的准确和及时的传达。分析前自动化包括在进行实际诊断测试之前对样本进行标记、分类和准备。此步骤对于减少分析前错误并提高诊断流程的整体效率至关重要。
最终用途:研究机构更喜欢高度可自订和可扩展的自动化解决方案。
临床实验室优先考虑高通量、准确性和最小错误率。自动化使得处理大量测试并获得一致的结果成为可能,这在高要求的环境中至关重要。这些实验室通常拥有广泛的测试组合,需要灵活的自动化来处理不同类型的检测和样本。医院需要支援快速週转时间并且易于整合到现有医院资讯系统中的自动化解决方案。其重点是即时检测和快速适应各种测试需求的能力,包括紧急和常规诊断测试。在研究实验室中,明显需要分子诊断的自动化,重点在于弹性、扩充性和准确性。这些设施专注于实验研究,需要能够准确适应各种分析和实验条件的设备。
区域洞察
美国和加拿大因其先进的医疗基础设施、大量的研发投资以及较高的人均医疗支出而在美洲地区处于领先地位。这些国家的需求因对各种疾病(包括感染疾病、癌症和遗传性疾病)更快、更准确的诊断测试的需求而增长。重点是整合资料管理系统和诊断设备,以简化工作流程并改善患者治疗结果。在医疗保健资金、严格的监管标准以及对先进诊断解决方案的高度认识的推动下,欧盟 (EU) 国家呈现出采用自动化分子诊断设备的强劲趋势。欧盟的 Horizon 2020 等倡议支持医疗保健领域的研究和创新,包括分子诊断,从而促进新技术和系统的开发。在中东,在沙乌地阿拉伯和阿联酋等国家大规模医疗投资的推动下,先进医疗技术的采用正在增加。包括中国、日本和印度在内的亚太地区在自动化分子诊断设备的采用方面显示出显着增长。这一增长的主要驱动力是医疗保健支出的增加、对疾病早期发现的认识以及政府改善医疗保健的努力。
FPNV定位矩阵
FPNV 定位矩阵对于评估分子诊断自动化市场至关重要。我们检视与业务策略和产品满意度相关的关键指标,以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估,供应商被分为四个成功程度不同的像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市场占有率分析
市场占有率分析是一种综合工具,可以对分子诊断自动化市场中供应商的现状进行深入而深入的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献,以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外,该分析还提供了对该行业竞争特征的宝贵见解,包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。这种详细程度的提高使供应商能够做出更明智的决策并制定有效的策略,从而在市场上获得竞争优势。
1. 市场渗透率:提供有关主要企业所服务的市场的全面资讯。
2. 市场开拓:我们深入研究利润丰厚的新兴市场,并分析其在成熟细分市场的渗透率。
3. 市场多元化:提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。
4.竞争力评估与资讯:对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况、製造能力等进行全面评估。
5. 产品开发与创新:提供对未来技术、研发活动和突破性产品开发的见解。
1. 分子诊断自动化市场的市场规模与预测为何?
2.分子诊断自动化市场预测期间需要考虑投资的产品、细分市场、应用和领域有哪些?
3.分子诊断自动化市场的技术趋势和法规结构是什么?
4.分子诊断自动化市场主要厂商的市场占有率为何?
5. 进入分子诊断自动化市场的合适型态和策略手段是什么?
[193 Pages Report] The Automation in the Molecular Diagnostics Market size was estimated at USD 11.75 billion in 2023 and expected to reach USD 13.54 billion in 2024, at a CAGR 15.79% to reach USD 32.81 billion by 2030.
Automation in molecular diagnostics refers to the use of advanced technologies and machinery to perform complex laboratory tests that detect and measure the presence of genetic materials, including DNA and RNA, in a patient's sample, including blood, saliva, and tissue. Unlike traditional methods that require significant manual effort and time, automation streamlines these processes, making them faster, more accurate, and capable of handling a large volume of tests simultaneously. The rising focus on personalized healthcare and precision medicine necessitates more efficient and accurate diagnostics. Moreover, the increasing incidence of chronic diseases worldwide boosts the demand for automated molecular diagnostics. Various government programs and funding in healthcare infrastructure and research encourage the adoption of these technologies. However, the initial investment in automation technology can be prohibitive for smaller labs and institutions. Furthermore, continuous innovations in automation technology, such as high-throughput systems and AI integration, drive the market forward. Integrating AI and machine learning to enhance data analysis and interpretation in diagnostics poses significant opportunities for manufacturers.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 11.75 billion |
Estimated Year [2024] | USD 13.54 billion |
Forecast Year [2030] | USD 32.81 billion |
CAGR (%) | 15.79% |
Type: Increasing significance of amplification automation in high-throughput settings
Amplification automation pertains to the process of amplifying & making multiple copies of the genetic material (DNA or RNA) to detectable levels. It is a crucial step in molecular diagnostics for identifying pathogens and genetic mutations and for any application requiring a significant quantity of genetic material for analysis. Amplification automation is particularly indispensable in high-throughput settings where a large number of samples need consistent and rapid processing, such as in infectious disease outbreaks or large-scale genetic testing. The automation segment of analysis involves the automated interpretation of amplified genetic material. This includes software-based analysis for variant detection, quantification, and mutation identification. Analysis automation is essential for laboratories aiming to minimize human error in data interpretation and those that require fast turnaround times without compromising accuracy. Extraction automation refers to the process of automatically extracting nucleic acids (DNA/RNA) from samples, which is the first step in most molecular diagnostic protocols. This type of automation ensures high purity and yield of nucleic acids, which is crucial for the success of subsequent diagnostic steps. Post-analytical automation involves the automated management of data post-analysis, including report generation, data storage, and result dissemination. This ensures accurate and timely communication of diagnostic results. Pre-analytical automation includes sample labeling, sorting, and preparation before the actual diagnostic tests are performed. This phase is essential for reducing pre-analytical errors and enhancing the overall efficiency of the diagnostic process.
End-use: Research institutions prefer highly customizable and scalable automation solutions
Clinical laboratories prioritize high throughput and accuracy with minimal error rates. Automation allows for the processing of a large volume of tests with consistent results, which is crucial in high-demand environments. These laboratories typically have a broader range of testing portfolios and require automation flexibility to handle various types of assays and samples. Hospitals require automation solutions that support rapid turnaround times and are easy to integrate into their existing hospital information systems. The focus is on point-of-care testing and the ability to quickly adapt to varied testing demands, including emergency and routine diagnostic tests. Research institutions have a distinct need for automation in molecular diagnostics, emphasizing flexibility, scalability, and precision. These establishments are focused on experimental research, requiring equipment that can accurately handle a wide variety of assays and experimental conditions.
Regional Insights
The United States and Canada are leading in the Americas region due to their advanced healthcare infrastructure, significant investment in research & development, and high healthcare expenditure per capita. The demand in these countries is accelerated by the need for quicker and more accurate diagnostic tests for a variety of diseases, including infectious diseases, cancer, and genetic disorders. There is a high emphasis on the integration of data management systems with diagnostic equipment to streamline workflows and improve patient outcomes. The European Union countries show a strong trend towards adopting automated molecular diagnostics, driven by the availability of healthcare funding, stringent regulatory standards, and a high degree of awareness about advanced diagnostic solutions. Initiatives such as the EU's Horizon 2020 have supported research and innovation in healthcare, including molecular diagnostics, leading to the development of new technologies and systems. The Middle East is experiencing growth in adopting advanced healthcare technologies due to substantial healthcare investments in countries including Saudi Arabia & UAE. The APAC region, encompassing countries including China, Japan, and India, has shown remarkable growth in the adoption of automated molecular diagnostics. The growth is primarily driven by rising healthcare expenditure and, awareness about early disease detection, and government initiatives towards healthcare improvement.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Automation in the Molecular Diagnostics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Automation in the Molecular Diagnostics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Automation in the Molecular Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Adaltis S.r.l., altona Diagnostics GmbH, AstraGene, Becton, Dickinson and Company, Biocartis, bioMerieux S.A., Danaher Corporation, ELITech Group, F. Hoffmann-La Roche Ltd., Hologic, Inc., MEGAROBO technologies Co., Ltd., Meridian Bioscience, Molecular Devices, LLC, Mylab Discovery Solutions, QIAGEN N.V., QuidelOrtho Corporation, Revvity, Inc., Sansure Biotech Inc., Scispot.io Inc., Seegene, Inc., Siemens Healthineers AG, Tecan Group Ltd., The Festo Group, and Vela Diagnostics.
Market Segmentation & Coverage
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
1. What is the market size and forecast of the Automation in the Molecular Diagnostics Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Automation in the Molecular Diagnostics Market?
3. What are the technology trends and regulatory frameworks in the Automation in the Molecular Diagnostics Market?
4. What is the market share of the leading vendors in the Automation in the Molecular Diagnostics Market?
5. Which modes and strategic moves are suitable for entering the Automation in the Molecular Diagnostics Market?